Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesSevere atypical HUS caused by CFH S1191L--case presentation and review of treatment options
Pediatric Nephrology, 11/04/09
De S et al. – Eculizumab, a monoclonal humanized anti–C5 antibody, has recently been shown to be effective and well–tolerated in patients with paroxysmal nocturnal hemoglobinuria by preventing complement–mediated lysis of affected erythrocytes. Treatment of the patient with eculizumab is supported by recent reports on its successful use in two (pediatric and adult) patients with complement–based aHUS.
Related Articles
Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation
American Journal of Kidney Diseases, 10/29/09
Relevance Score: 83%
Today in Pediatrics...keeping you current
Receive free subspecialty "5-minute updates" via email
Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis
Pediatric Blood & Cancer, 11/25/09
Axenfeld-Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion
Pediatric Blood & Cancer, 11/25/09
Respiratory syncytial virus infections in Central Australia
Journal of Paediatrics and Child Health, 11/25/09
Article Search
Sponsor